Pneumonia Diagnostics & Technologies Market - Forecast(2024 - 2030)

The Pneumonia Diagnostics & Technologies Market size is estimated to reach $3.8 billion by 2028, growing at a CAGR of 8.5% during the forecast period 2023-2028. By product type, Pneumonia Diagnostics & Technologies Market can be segmented into consumables and analyzers. Immunodiagnostics utilizes the capability of antibodies to particularly bind to an antigen of interest. Molecular diagnostics has been the single principal development in pneumonia diagnostics over recent years. Point-of-care testing is a laboratory-medicine discipline that is maturing very quickly in analytical scope and clinical application. Moreover, an Enzyme-linked Immunosorbent Assay (ELISA) with a greatly purified pneumolysin as the antigen was measured for serological diagnosis of pneumococcal pneumonia. The increasing pervasiveness of pneumonia among the elderly is set to drive the Pneumonia Diagnostics & Technologies Market. The growing R&D activities in the healthcare sector are set to propel the growth of the Pneumonia Diagnostics & Technologies industry during the forecast period 2023-2028. This represents the Pneumonia Diagnostics & Technologies Industry Outlook.

Pneumonia Diagnostics & Technologies Market Report Coverage

The “Pneumonia Diagnostics & Technologies Market Report - Forecast (2023-2028)” by IndustryARC, covers an in-depth analysis of the following segments in the Pneumonia Diagnostics & Technologies Market.

By Product Type: Consumables, Analyzers.
By Technique: Immunodiagnostics, Molecular Diagnostics, Point of Care Testing and Others.
By Geography: North America (the US, Canada and Mexico), Europe (Germany, France, the UK, Italy, Spain, Russia and the Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand and the Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia and the Rest of South America) and the Rest of the World (the Middle East and Africa).

Key Takeaways

• Geographically, North America (Pneumonia Diagnostics & Technologies market share) accounted for the highest revenue share in 2022 and it is poised to dominate the market over the period 2023-2028 owing to the dominance of Enzyme-linked Immunosorbent Assay (ELISA) technology in the region.
• The growth of the Pneumonia Diagnostics & Technologies Market is being driven by the increasing predominance of pneumonia among children. However, it is hard to diagnose pneumonia since its clinical symptoms overlap with other ailments like asthma. This is one of the major factors hampering the growth of the Pneumonia Diagnostics & Technologies Market.
• The Pneumonia Diagnostics & Technologies Market Detailed Analysis of the Strengths, Weaknesses and Opportunities of the prominent players operating in the market would be provided in the Pneumonia Diagnostics & Technologies Market report. 

Pneumonia Diagnostics & Technologies Market Segment Analysis - by Product Type

The Pneumonia Diagnostics & Technologies Market based on product type can be further segmented into Consumables and Analyzers. The Analyzers Segment held the largest share of the Pneumonia Diagnostics & Technologies market in 2022. This growth is fueled by the frequent application of analyzers for pneumonia tests across the world. Hematology analyzers and basic analyzers are used extensively in blood tests as required for treating patients. The increasing diagnosis of pneumonia through the application of blood tests is further propelling the growth of the Analyzers segment.

Furthermore, the Consumables segment is estimated to grow at the fastest CAGR of 9.3% during the forecast period 2023-2028. This is due to the snowballing application of chest x-rays involving x-ray consumables for diagnosis of pneumonia which further assist the physicians in deciding the extent and location of the infection.

Pneumonia Diagnostics & Technologies Market Segment Analysis - by Technique

The Pneumonia Diagnostics & Technologies Market based on technique can be further segmented into Immunodiagnostics, Molecular Diagnostics, Point-of-Care Testing and Others. The Point-of-Care Testing Segment held the largest share of the Pneumonia Diagnostics & Technologies market in 2022. This growth is driven by the growing application of point-of-care testing for the diagnosis of pneumonia across the world. The expanding population of the elderly, sedentary lifestyle, unhealthy food habits and environmental factors are contributing to the increasing count of cases of pneumonia. The enhanced effectiveness and accelerated test outcomes are further propelling the growth of this segment.

Furthermore, the Immunodiagnostics segment is estimated to grow at the fastest CAGR of 9.5% during the forecast period 2023-2028. This is due to the soaring application of Immunodiagnostics for the detection of community-acquired pneumonia among children.

Pneumonia Diagnostics & Technologies Market Segment Analysis - by Geography

The Pneumonia Diagnostics & Technologies Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America and the Rest of the World. North America (Pneumonia Diagnostics & Technologies Market) dominated the global Pneumonia Diagnostics & Technologies market with a 32% share of the overall market in 2022. The growth of this region is fueled by the increasingly devastating impacts of pneumonia on babies and the elderly in the North American region. The world-class healthcare infrastructure in the U.S. is further propelling the growth of the Pneumonia Diagnostics & Technologies Industry, thereby contributing to the Pneumonia Diagnostics & Technologies Industry Outlook, in the North American region.

Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR over the forecast period 2023-2028. This growth is driven by factors like the increasing predominance of pneumonia in the Asia-Pacific region. The rising point-of-care testing is further fueling the progress of the Pneumonia Diagnostics & Technologies Market in the Asia-Pacific region.

Pneumonia Diagnostics & Technologies Market Drivers

Vital Significance of Molecular Diagnostics in Pneumonia:

As per the Centers for Disease Control and Prevention (CDC), the percentage of adults aged 18 and over, who had ever accepted a pneumococcal vaccination, is 25.5% in 2020. Molecular methods have the potential to enhance diagnostic yield and reduce the time to pathogen recognition. These methods are also beneficial in the determination of drug sensitivity and the comprehension of transmission and outbreaks. Molecular diagnosis of pneumonia has the potential to enhance the recognition of pathogens in patients with suspected lower respiratory tract infections. The vital significance of Molecular Diagnostics in Pneumonia is therefore fueling the growth of the Pneumonia Diagnostics & Technologies Market during the forecast period 2023-2028.

Surging Investigations Involving Diagnosis of Pneumococcal Pneumonia by Enzyme-linked Immunosorbent Assay:

An Enzyme-linked Immunosorbent Assay (ELISA) with a greatly purified pneumolysin as the antigen was checked for serological diagnosis of pneumococcal pneumonia. One hundred four healthy controls were tested and the particularity of the test was set to 95%. In samples from patients with bacteremic pneumococcal pneumonia, 82% (18 of 22) were positive. Serum immunoglobulin G response to pneumolysin as calculated by ELISA may therefore be a support in the laboratory diagnosis of pneumococcal pneumonia. The surging investigations involving the diagnosis of pneumococcal pneumonia by Enzyme-linked Immunosorbent Assay are therefore driving the growth of the Pneumonia Diagnostics & Technologies Industry. This contributes to the Pneumonia Diagnostics & Technologies Industry Outlook during the forecast period 2023-2028.

Pneumonia Diagnostics & Technologies Market Challenges

Issues with Diagnostic Techniques of Pneumonia:

As per the Centers for Disease Control and Prevention (CDC), the count of visits to emergency departments with pneumonia as the primary diagnosis is 1.5 million. Clinical criteria of pneumonia, including fever, purulent tracheobronchial secretions, leukocytosis and a novel infiltrate on chest radiograph are hampered by the high frequency with which these findings are observed in patients without pneumonia. Blood cultures are priceless when positive. However, negative outcomes are more typical even in severe pneumonia. These issues are thus hampering the growth of the Pneumonia Diagnostics & Technologies Market.

Pneumonia Diagnostics & Technologies Industry Outlook

Novel product launches, mergers and acquisitions, partnerships, collaborations and R&D activities are key strategies adopted by players in the Pneumonia Diagnostics & Technologies Market. The top 10 companies in the Pneumonia Diagnostics & Technologies market are:

1. Becton, Dickinson and Company (BD)
2. Affymetrix (Thermo Fisher Scientific)
3. Bio-Rad Laboratories, Inc.
4. Abbott Laboratories
5. F. Hoffmann-La Roche AG.
6. GSK plc
7. bioMérieux SA
8. DiaSorin
9. Hologic, Inc.
10. Fujirebio

Recent Developments

• In August 2021, BD (Becton, Dickinson and Company) declared that it has introduced a novel, completely automated high-throughput diagnostic system. This utilizes robotics and sample management software algorithms. This is to set new standards in automation for infectious disease molecular testing.
• In July 2021, BD declared the acquisition of Tepha, Inc. Tepha, Inc. is a chief manufacturer of proprietary resorbable polymer technology. Tepha's proprietary resorbable polymer (Poly 4-hydroxybutyric acid, P4HB) technology platform offers added innovation potential.
• In July 2021, BD declared the commercial release of a new bdbiosciences.com web and eCommerce site. This is a completely "reimagined" digital marketplace. It is planned to offer an improved online purchasing experience.

Relevant Reports:

Clostridium Diagnostics Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis
Report Code: HCR 0835

In Vitro Toxicology Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis
Report Code: FBR 0113

In Vitro Diagnostics Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis
Report Code: HCR 0577

For more Lifesciences and Healthcare Market reports, please click here